VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis

Expert Opinion on Investigational Drugs

Volumn 20, Issue 7, 2011, Pages 981-986

  Horak, Friedrich ^a  

^a Allergy Centre Vienna West   (Austria)

Author keywords

allergic rhinitis treatment; IL 12 production; immunomodulation; nasal spray; TLR8; Toll like receptor agonist; Vienna challenge chamber; VTX 1463

Indexed keywords

ANTIHISTAMINIC AGENT; DECONGESTIVE AGENT; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; RAGWEED ANTIGEN; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VTX 1463; VTX 378;

ALLERGIC RHINITIS; ARTICLE; COGNITIVE DEFECT; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; EPISTAXIS; GRASS POLLEN; HEART PALPITATION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; NONHUMAN; NOSE CONGESTION; NOSE IRRITATION; NOSE SECRETION; PERENNIAL RHINITIS; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOMANOMETRY; RHINORRHEA; SEDATION; SIDE EFFECT; SUBCUTANEOUS IMMUNOTHERAPY; TACHYCARDIA; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-ALLERGIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TOLL-LIKE RECEPTOR 8;

EID: 79958832035     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.583237     Document Type: Article

References (29)

1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28(1):3-9
2. Shedden AS. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Treat Respir Med 2005;4(6):439-46
3. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160 (Pubitemid 351357811)
4. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2007;28(2):145-52
5. Cingi C, Kayabasoglu G, Nacar A. Update on the medical treatment of allergic rhinitis. Inflamm Allergy Drug Targets 2009;8(2):96-103
6. Baiardini I, Braido F, Tarantini F, et al. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008;63(6):660-9 (Pubitemid 351591849)
7. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104(1):13-29
8. Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 2003;90(6 Suppl 3):7-12 (Pubitemid 36712683)
9. Pawankar R, Bunnag C, Chen Y, et al. Allergic rhinitis and its impact on asthma update (ARIA 2008)-western and Asian-Pacific perspective. Asian Pac J Allergy Immunol 2009;27(4):237-43
10. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004;112(3):352-63 (Pubitemid 38859512)
11. Weiss ST. Eat dirt-the hygiene hypothesis and allergic diseases. N Engl J Med 2002;347(12):930-1
12. Hennessy EJ, Parker AE, O'Neill LAJ. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010;9:293-307
13. Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med 2007;13(5):552-9 (Pubitemid 46830615)
14. Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121(2):288-96 (Pubitemid 351215187)
15. Drachenberg KJ, Wheeler A, Stubner UP, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56(6):498-505 (Pubitemid 32521429)
16. Drachenberg KJ, Wheeler AW, Woroniecki SR, et al. A Th1 inducing adjuvant, MPL®, safely assists in reducing the length of a pollen allergy vaccination course. Allergol Immunol Clin 2002;17:39-43 (Pubitemid 34408040)
17. McCormack PL, Wagstaff AJ. Ultra-short-courseseasonal allergy vaccine (Pollinex Quatro). Drugs 2006;66:377-82
18. DuBuske L, Frew A, Horak F, et al. Ultra-short specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; In press
19. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a Ragweek-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis. N Eng J Med 2006;355:1445-55 (Pubitemid 44511559)
20. Holtick U, Scheulen ME, Bergwelt-Baildon MS, et al. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 2011;20(3):361-72
21. Casale TB, Kessler J, Romero FA. Safety of the intranasal Toll-like receptor 4 agonist CRX-675 in allergic disease. Ann Allergy Asthma Immunol 2006;97:454-6 (Pubitemid 44595091)
22. Moller-Larsen S, Nyegaard M, Haagerup A, et al. Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax 2008;63(12):1064-9
23. Sel S, Wegmann M, Sel S, et al. Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-101. J Immun 2007;178:7805-13 (Pubitemid 46898052)
24. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immun 2005;174:1259-68
25. Rudolf K, Bice DE, Hey JA, et al. A model of allergic nasal congestion in dogs sensitized to ragweed. Am J Rhinol 2003;17:227-32 (Pubitemid 37098503)
26. Barrett EG, Rudolph K, Dietsch D, et al. VTX-378, A novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs. JACI 2011;127(2 Suppl):abstract 268
27. Day JH, Horak F, Briscoe MP, et al. The role of allergen challenge chambers in the evaluation of antiallergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6(2):31-59
28. Horak F, Jager S. The Vienna Challenge Chamber (VCC)-A new method for environmental exposition. Wien Klin Woschenschr 1987;99(14):509-10
29. Horak F, Zieglmayer P, Zieglmayer R, et al. Intranasal Toll-like receptor 8 agonist (VTX-1463) significantly improves symptoms of allergic rhinitis in a randomized, placebo-controlled trial. JACI 2011:127:2(Suppl):abstract 199